Characterization of human IgG antimouse antibody in patients with B-cell malignancies

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  DeNardo, Gerald L ^a,c   Mirick, Gary R ^a   Kroger, Linda A ^a   Bradt, Bonnie M ^a   Lamborn, Kathleen R ^b   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Radiodiagnosis and Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HUMAN ANTIMOUSE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY LYM 1; MONOCLONAL ANTIBODY LYM 1 CU 67; MONOCLONAL ANTIBODY LYM 1 I 125; MONOCLONAL ANTIBODY LYM 1 I 131; MONOCLONAL ANTIBODY LYM 1 IN 111; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; B CELL LYMPHOMA; BLOOD SAMPLING; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; FEMALE; HUMAN; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SEROCONVERSION; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, B-CELL, CHRONIC; LYMPHOMA, NON-HODGKIN; MALE; MICE; MIDDLE AGED;

EID: 0141456526     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. DeNardo, G. L., Bradt, B. M., Mirick, G. R., and DeNardo, S. J. Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol. Immunother., 52: 309-316, 2003.
2. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., and Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 16: 2825-2833, 1998.
3. Wiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Bartlett, N. L., Parker, J. A., Dunn, W. L., Spies, S. M., Belanger, R., Witzig, T. E., and Leigh, B. R. Biodistribution and dosimetry results from a Phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit. Rev. Oncol. Hematol., 39: 181-194, 2001.
4. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multani, P., and White, C. A. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 20: 2453-2463, 2002.
5. Kaminiski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., Wahl, R. L., Knox, S. J., and Vose, J. M. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol., 19: 3918-3928, 2001.
6. Johnson, T. A., and Press, O. W. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann. Hematol., 79; 175-182, 2000.
7. Juweid, M., Sharkey, R. M., Markowitz, A., Behr, T. M., Swayne, L. C., Dunn, R., Hansen, H. J., Shevitz, J., Leung, S. O., Rubin, A. D., Herskovic, T., Hanley, D., and Goldenberg, D. M. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 55: 5899s-5907s, 1995.
8. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol., 16: 3246-3256, 1998.
9. 131I-Lym-1. Int. J. Biol. Mark., 10: 67-74, 1995.
10. 131I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma: update results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259-1266, 2000.
11. 90Y-labeled anti-CD20 monoclonal antibody. Clin. Cancer Res. 5: 3281s-3286s, 1999.
12. Khazaeli, M. B., Conry, M., and LoBuglio, A. F. Human immune response to monoclonal antibodies. J. Immunother., 15: 42-52, 1994.
13. 67Cu-2IT-BAT-Lym-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res., 18: 2779-2788, 1998.
14. Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F. M., Parker, J. W., and Taylor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
15. Rose, L. M., Gunasekera, A. H., DeNardo, S. J., DeNardo, G. L., and Meares, C. F. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol. Immunother., 43: 26-30, 1996.
16. DeNardo, G. L., Mills, S. L., Kukis, D. L., Anderson, V., and DeNardo, S. J. Review of a four-year experience iodinating monoclonal antibodies with therapeutic amounts of 1-131. Antib. Immunoconj. Radiophar., 8: 1-10, 1995.
17. Mills, S. L., DeNardo, S. J., DeNardo, G. L., Deshpande, S. V., McCall, M. J., Meares, C. F., and Epstein, A. L. Radiopharmaceutical preparation of a monoclonal antibody, Lym-1, and its F(ab′)2 fragment for imaging lymphoma with In-111. J. Labelled Compounds Radiopharm., 27: 377-386, 1989.
18. Kukis, D. L., DeNardo, G. L., DeNardo, S. J., Mirick, G. R., Miers, L. A., Greiner, D. P., and Meares, C. F. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res., 55: 878-884, 1995.
19. DeNardo, S. J., Kroger, L. A., MacKenzie, M. R., Mirick, G. R., Shen, S., and DeNardo, G. L. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. Cancer Biother. Radiopharm., 13: 1-12, 1998.
20. Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., and Morgan, A. C., Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res., 45: 879-885, 1985.
21. HAMA Survey Group. Survey of methods for measuring human anti-mouse antibodies. Clinica Chimica Acta, 215: 153-163, 1993.
22. Hollander, M., and Wolfe, D. A. Nonparametric Statistical Methods. New York: Wiley, 1973.
23. Fleiss, J. L. Statistical Methods for Rates and Proportions, p. 25. New York: Wiley, 1973.
24. Goodman, G. E., Hellstrom, I., Brodzinsky, L., Nicaise, C., Kulander, B., Hummel, D., and Hellstrom, K. E. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer. J. Clin. Oncol., 8: 1083-1092, 1990.
25. Ziegler, L. D., Palazzolo, P., Cunningham, J., Janus, M., Itoh, K., Hayakawa, K., Hellstrom, I., Hellstrom, K. E., Nicaise, C., and Dennin, R. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J. Clin. Oncol., 10: 1470-1478, 1992.
26. Gupta, S. Immunodeficiencies in Hodgkin's Disease. Part I: T-cell mediated immunity, Part II: B cell immunity, complement systems and phagocytic cell systems. Clin. Bull., 11: 58-119, 1981.
27. Shawler, D. L., Bartholomew, R. M., Smith, L. M., and Dillman, R. O. Human immune response to multiple injections of murine monoclonal IgG1. J. Immunol., 135: 1530-1535, 1985.
28. Khazaeli, M. B., Saleh, M. N., Liu, T., Kaladas, P. M., Gilman, S. C., and LoBuglio, A. F. Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody. J. Clin. Immunol., 12: 116-121, 1992.
29. Colcher, D., Milenic, D. E., Ferroni, P., Carrasquillo, J. A., Reynolds, J. C., Roselli, M., Larson, S. M., and Schlom, J. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J. Nucl. Med., 31: 1133-1142, 1990.
30. Seccamani, E., Tattanelli, M., Mariani, M., Spranzi, E., Scassellati, G. A., and Siccardi, A. G. A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int. J. Rad. Appl. Instrum. B, 16: 167-170, 1989.
31. Kuus-Reichel, K., Grauer, L. S., Karavodin, L. M., Knott, C., Krusemeier, M., and Kay, N. E. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol., 1: 365-372, 1994.
32. LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., and Khazaeli, M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA, 86: 4220-4224, 1989.
33. Mittelman, A., Chen, Z. J., Yang, H., Wong, G. Y., and Ferrone, S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA, 89: 466-470, 1992.
34. Herlyn, D., and Birebent, B. Advances in cancer vaccine development. Ann. Med., 31: 66-78, 1999.
35. Bhattacharya-Chatterjee, M., Chatterjee, S. K., and Foon, K. A. Anti-idiotype vaccine against cancer. Immunol. Lett., 74: 51-58, 2000.
36. Wiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Barlett, N. L., Parker, J. A., Dunn, W. L., Spies, S. M., Belanger, R., Witzig, T. E., and Leigh, B. R. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit. Rev. Oncol. Hematol., 39: 181-194, 2001.
37. Kaminski, M. S., Zelentz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Knoll, S., Wahl, R. L., Knox, S. J., Vose, J. M. Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19: 3918-3928, 2001.
38. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J. A., Capdeville, R., Diehl, V., and Reyes, F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood, 92: 1927-1932, 1998.
39. 131I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259-1266, 2000.
40. Kaminski, M., Zasadny, K., Francis, L., Fenner, M., Ross, C., Milik, A., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S., and Wald, R. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1991, 1996.
41. 131I] anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.